Biodistribution of Yttrium-90–Labeled Anti-CD45 Antibody in a Nonhuman Primate Model

Eneida R. Nemecek,1,2 Donald K. Hamlin,5 Darrell R. Fisher,6 Kenneth A. Krohn,4 John M. Pagel,1,3 Frederick R. Appelbaum,1,3 Oliver W. Press,1,3 and Dana C. Matthews1,2

1Division of Clinical Research, Fred Hutchinson Cancer Research Center; Departments of 2Pediatrics, 3Medicine, 4Radiology, and 5Radiation Oncology, University of Washington, Seattle, Washington; and 6Pacific Northwest National Laboratories, Richland, Washington

ABSTRACT

Purpose: Radioimmunotherapy may improve the outcome of hematopoietic cell transplantation for hematologic malignancies by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the organ localization of yttrium-90-labeled anti-CD45 (90Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 (131I-anti-CD45) antibody biodistribution in humans.

Experimental Design: Twelve Macaca nemestrina primates received anti-CD45 antibody labeled with 1 to 2 mCi of 90Y followed by serial blood sampling and marrow and lymph node biopsies, and necropsy. The content of 90Y per gram of tissue was determined by liquid scintillation spectrometry. Time-activity curves were constructed using average isotope concentrations in each tissue at measured time points to yield the fractional residence time and estimate average isotope concentrations in each tissue at measured time points.

Results: The spleen received 2,120, marrow 1,060, and lymph nodes 315 cGy/mCi of 90Y injected. The liver and lungs were the nontarget organs receiving the highest radiation absorbed doses (440 and 285 cGy/mCi, respectively). Yttrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively. The ratios previously observed with 131I-anti-CD45 antibody were 2.5-and 2.2-fold more radiation to marrow than to liver and lungs, respectively.

Conclusions: This study shows that 90Y-anti-CD45 antibody can deliver selectively radiation to hematopoietic tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model.

INTRODUCTION

Allogeneic hematopoietic cell transplantation can cure many patients with hematologic malignancies, but relapse remains the major cause of treatment failure. Intensifying transplant preparative regimens with systemic chemotherapy and radiotherapy decreases the rate of relapse but increases the risk of transplant-related morbidity and mortality (1–4). Monoclonal antibodies reactive with hematopoietic antigens have been used as potential vehicles to deliver targeted chemotherapy or radiation therapy to sites of leukemia and lymphoma involvement (5–11). The delivery of supplemental radiation to target hematopoietic organs, with relative sparing of other nontarget organs, may decrease the risk of posttransplant relapse without excessively increasing transplant-related toxicity.

The CD45 antigen is a tyrosine phosphatase present on the surface of most nucleated hematopoietic cells, lymphoblasts, and myeloblasts, but not on the surface of nonhematopoietic cells (12, 13). This antigen is expressed in a relatively high copy number (200,000 binding sites per cell) and is not appreciably internalized after ligand binding (14, 15). Radiolabeled antibodies exert their cytotoxic effect by either directly killing antigen-positive cells to which they bind or by killing neighboring cells within a mean path length specific for each radionuclide (16). This mechanism, known as bystander effect, poses a potential advantage when treating malignancies with heterogeneous antigen expression, such as leukemia and lymphoma, in which the antibody may not bind to every malignant cell. Given this bystander effect and the relatively high expression of CD45 antigen by normal and abnormal hematopoietic cells, a radioactive moiety attached to an anti-CD45 antibody can deliver radiation to residual leukemia cells, even in the setting of disease remission.

The ability of iodine-131-labeled anti-CD45 antibody to deliver radiation relatively selectively to hematopoietic tissues has been shown previously in mice, macaques and humans (5, 6, 17–19). Clinical studies of 131I-anti-CD45 antibody combined with conventional transplant regimens have shown that this antibody can deliver at least twice as much radiation to hematopoietic organs compared with nontarget organs (5, 6). Although preliminary results of these clinical studies are encouraging, treatment still fails in many patients because of relapse or transplant-related complications, indicating the need to further improve current radioimmunotherapy methods. One approach to improve the delivery of radiation to target organs is the use of alternative radionuclides.

The β emitter, yttrium-90, has several physical properties that may result in improved ratios of radiation delivered to target compared with nontarget organs (5, 20). Unpublished preliminary studies of 90Y-anti-CD45 antibody in mice done by our group showed longer retention of radionuclide in the target tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model.
tissues of marrow and spleen compared with $^{131}$I but also longer retention of $^{90}$Y in the liver. Because the relative organ concentration and retention of radiolabeled antibody may differ between mice and larger animals, we tested the hypothesis that superior delivery of radiation to target organs could be achieved with $^{90}$Y in a nonhuman primate model. The biodistribution of $^{131}$I-anti-CD45 antibody in previous macaque studies closely resembled the biodistribution subsequently observed for $^{131}$I-anti-CD45 antibody in humans (5, 19). The macaque model also allows extensive tissue sampling and thus direct measurement of $^{90}$Y in organs of interest.

In this study, we examined the relative organ localization and retention (i.e., biodistribution) of $^{90}$Y-anti-CD45 antibody in macaques using direct quantitative methods and compared the results to those previously obtained with $^{131}$I-anti-CD45 antibody in the same animal model.

**MATERIALS AND METHODS**

**Animals**

Twelve *Macaca nemestrina* males were obtained from and housed at the Washington National Primate Research Center of the University of Washington (Seattle, WA). The median age of the animals was 5 years (4 to 6 years), and the median weight was 7.5 kg (4.3 to 9 kg). Animal care and procedures were done in accordance to the guidelines from the Institute of Laboratory Animal Resources of the National Research Council, National Academy of Sciences, and with approval of the Institutional Animal Care and Use Committee.

**Monoclonal Antibody**

The monoclonal antibody AC8 is a murine IgG2a isotype that recognizes CD45 antigen of nonhuman primates, binding approximately $2 \times 10^7$ CD45 molecules per cell, with an association constant (avidity) of $5 \times 10^8$ L/mol (19, 21). Hybridoma cells secreting the AC8 antibody were provided by W. Michael Gallatin (Fred Hutchinson Cancer Research Center, Seattle, WA). Ascites was produced by inoculating the hybridoma cells into specific pathogen-free mice. The antibody was purified by batch extraction and high-performance liquid chromatography with ABX exchange resin (J.T. Baker, Phillipsburgh, NJ). The eluted antibody was pooled, concentrated, and diafiltered through a PM-10 ultrafiltration membrane (Amicon Corp, Danvers, MA) into PBS (pH 7.2; 140 mmol/L NaCl, 8 mmol/L Na$_2$HPO$_4$, 2.7 mmol/L KCl, 1.5 mmol/L KH$_2$PO$_4$). The concentration of antibody was determined using a modified bicinchoninic acid protein assay (Pierce Chemical, Rockford, IL), standardized with bovine serum albumin. The antibody was aliquoted and stored at $-70^\circ$C until use.

**Conjugation, Radiolabeling, and Characterization of the Antibody**

The antibody conjugate was prepared using methods previously described (22). All reagents and laboratory ware used for conjugation and radiolabeling were metal free. Buffers were prepared with metal-free (18 $\Omega$) water, passed over a column of Chelex 100 resin (BioRad, Hercules, CA) and sterile filtered. Plastic laboratory ware was acid washed in 1% nitric acid followed by rinsing with metal-free water. The AC8 antibody (150 mg, 15 mg/mL) was placed in a Slide-A-Lyzer 10K cassette (Pierce, Rockford, IL) and dialyzed against 4 L of saline buffer (150 mmol/L NaCl, 1 mmol/L EDTA, pH 7.0) with six buffer changes, adding 5 g of Chelex-100 resin with each buffer change, at 4°C over 3 days. The dialyzed antibody (133 mg/9.2 mL) was mixed with 9.2 mL of HEPES buffer (100 mmol/L N-[2-hydroxyethyl]piperazine-$N\prime$-ethanesulfonic acid, 150 mmol/L NaCl, and 1 mmol/L EDTA, pH 8.5) and conjugated to 5.6 mg of 1,4,7,10-tetra-azacyclododecane $N\prime\prime$-$N\,'\prime\prime$-$N\,'$-$N\,'\prime\prime$-$N\,'\prime\prime$-tetraacetic isothiocyanate (DOTA-NCS, Macrocyclics, Dallas, TX) at room temperature for 12 hours. The antibody conjugate was then dialyzed twice against 4 L of citrate buffer (50 mmol/L Na citrate, 150 mmol/L NaCl, pH 5.5) containing 5 g of Chelex-100 resin followed by 6 $\times$ 4 L of saline (150 mmol/L NaCl, pH 7.0). The antibody was 99% pure, as confirmed by high-performance liquid chromatography and isoelectric focusing gel electrophoresis. The antibody concentration was determined to be 6 mg/mL by UV absorption at 280 nm (UV$_{280}$) using a DU520 spectrophotometer (Beckman Coulter, Allendale, NJ). The final product was sterile filtered and stored in metal-free vials at 4°C until use.

An aliquot of AC8-DOTA conjugate was diluted 1:1 with 0.5 mol/L ammonium acetate (pH 5.3) and 1.5 to 2 mCi of $^{90}$Y-chloride (Perkin-Elmer, Boston, MA) were added. The reaction mixture was incubated at 37°C for 1 hour, passed through a PD-10 column (G-25 Sephadex, Pharmacia, Piscataway, NJ) and eluted with 0.9% saline. The protein fractions were combined and the final antibody concentration determined by UV$_{280}$. The radiolabeling yield was 85% to 95%. The pooled fractions of $^{90}$Y-AC8 antibody were tested for immunoreactivity using a modified cell-binding assay with macaque peripheral blood lymphocytes, as previously described (23). Known amounts of antibody were diluted in RPMI 1640 (Invitrogen, Grand Island, NY) with 1% bovine serum albumin (Sigma, St. Louis, MO) and incubated with (2 to 3) $\times 10^5$ cells for 1 hour at room temperature. Cells were washed twice after incubation, and bound radioactivity was counted. The final radiolabeled antibody product retained 75% or greater of its baseline immunoreactivity after radiolabeling and was more than 97% pure, as determined by cellulose acetate electrophoresis. The fraction of radiolabeled antibody product was combined with cold AC8 antibody to a total dose of 0.5 mg/kg antibody, diluted in PBS to a final volume of 10 mL. We chose to administer 0.5 mg/kg of AC8 antibody because the biodistribution of this non–antigen saturating dose of $^{131}$I-AC8 antibody in previous macaque studies proved to be very similar to the biodistribution of 0.5 mg/kg of $^{131}$I-BC8 antibody subsequently observed in humans (5, 19).

**Antibody Localization Studies**

Animals received a single i.v. injection of $^{90}$Y-AC8 antibody over 10 minutes, under general anesthesia. They were monitored for cardiorespiratory and physical status changes during the infusion and daily until euthanasia. Blood samples were obtained before the antibody infusion, at the end of the infusion (hour 0), and 0.5, 1, 2, 24, 48, and 96 hours postsinjection to measure complete blood counts, serum chemistries, and $^{90}$Y activity. Bone marrow and femoral lymph node excisional biopsies were obtained at 2 ($n$ = 12), 24 ($n$ = 9), 48 ($n$ = 6), and 96 ($n$ = 3) hours after the antibody infusion. Bone marrow core biopsies were done using a Jamshidi needle (Baxter,
RESULTS

Effects of 90Y-AC8 Antibody Infusion

The antibody infusion was well tolerated in all animals and there were no infusion-related acute side effects. No abnormalities were observed in serum electrolytes, liver enzymes, creatinine, hematocrit, or platelet counts (data not shown). There were no significant changes in peripheral white blood cell or monocyte counts (Fig. 1). Lower lymphocyte counts ($P < 0.0001$, Kruskal-Wallis test) and increased neutrophil counts ($P = 0.027$) were observed over time. The mean (95% confidence interval) decrease in lymphocytes from the time of infusion to 96 hours postinfusion was 2175 (1130-3219) cells/mL or 55% (38-71%). The mean increase in neutrophils was 2771 (750-4792) cells/µL or 56% (35-77%).

Organ Biodistribution

Clearance of the antibody from blood was biphasic (Fig. 2). There was a short initial $t_{1/2}$ (0.4 ± 0.1 hours) and a longer $\beta$ $t_{1/2}$ (14.7 ± 5.5 hours). More than 90% of the activity was cleared from blood within 24 hours after the infusion. The concentration of antibody in hematopoietic organs was higher than in nontarget organs, with spleen and marrow having the highest radiation uptake (Fig. 3). The activity at 24 hours was 2.31 ± 0.20 in spleen, 1.63 ± 0.21 in marrow, and 0.40 ± 0.04 %ID/g in lymph nodes. The highest uptake in spleen was observed immediately after the antibody infusion, likely reflecting the rapid blood pooling in this organ. Marrow and lymph nodes had their highest uptake approximately 24 hours after the antibody infusion. The nontarget organ with the highest radiation uptake was the liver followed by lungs and kidney. The highest activity in nontarget organs was observed immediately after the antibody infusion. The activity at 24 hours was 0.33 ± 0.05 in liver, 0.27 ± 0.03 in lungs, and 0.13 ± 0.02 %ID/g in kidneys. The radiation uptake for other nontarget organs was negligible, never exceeding 0.05 %ID/g (data not shown). Retention of activity in nontarget organs was minimal after 48 hours.

Similarly, our previous studies with 131I-AC8 showed blood clearance to be biphasic, with an initial $t_{1/2}$ of 0.6 ± 0.1 hours and a $\beta$ $t_{1/2}$ of 56.5 ± 25.4 hours (Fig. 2; ref. 19). The activity at 24 hours was 0.78 ± 0.02 in spleen, 0.11 ± 0.05 in marrow, 0.12 ± 0.03 in lymph nodes, 0.07 ± 0.02 in liver, 0.06 ± 0.04 in lungs, and 0.01 ± 0.001 %ID/g in kidneys (Fig. 3). All target and nontarget organs had their highest radiation uptake immediately after the antibody infusion. The nontarget organs having the highest radiation uptake were liver and lungs. Compared to 131I-AC8 antibody, 90Y-AC8 antibody resulted in higher activity in marrow, liver, lungs, and kidneys for the first 24 hours and in similar activity after 48 hours.
Estimated Radiation Absorbed Doses

The estimated radiation absorbed doses were higher for bone marrow and spleen than for nontarget organs (Table 1). The liver was the nontarget organ receiving the highest radiation dose. The ⁹⁰Y-AC8 antibody delivered 4.8 times greater radiation to the spleen and 2.5 times greater radiation to the marrow than to the liver. The dose to lymph nodes was 28% lower than the dose to liver. The dose to spleen was 7.4 times greater and the dose to marrow was 3.7 times greater than that to the lungs, the nontarget organ receiving the second highest radiation dose.

Table 2 summarizes the ratio of estimated radiation absorbed doses to target versus nontarget organs (i.e., therapeutic ratio) achieved with ⁹⁰Y- or ¹³¹I-labeled AC8 antibody for an average animal. Both radioimmunoconjugates delivered higher doses of radiation to spleen and marrow than to nontarget organs. Compared to ¹³¹I-labeled antibody, ⁹⁰Y-labeled antibody resulted in a higher ratio (168%) of marrow to lung, and in lower ratios of lymph node to liver (30%) and spleen to liver (50%). All other ratios were similar for both radioimmunoconjugates.

DISCUSSION

This study shows the ability of ⁹⁰Y-labeled anti-CD45 antibody to deliver relatively targeted radiation to hematopoietic tissues. The marrow to nontarget organ ratio of radiation observed with ⁹⁰Y-labeled anti-CD45 antibody is similar to that achieved with the ¹³¹I-labeled antibody.

In previous macaque experiments, we evaluated the biodistribution and dosimetry of two ¹³¹I-labeled antibodies reactive with the CD45 antigen of nonhuman primates (19). The animals received either 0.5 mg/kg of ¹³¹I-BC8, an antibody reactive with human CD45 with moderate avidity and nonhuman primate CD45 with low avidity, or 0.5 mg/kg (low dose) or 4.5 mg/kg (high dose) of ¹³¹I-AC8 antibody, an antibody reactive with nonhuman primate CD45 with moderate avidity. Organ residence times for ¹³¹I were generated from serial quantitative images and direct measurement of ¹³¹I concentration in tissue samples. The extent and pattern of antibody bound to target cells was

---

**Fig. 1** Peripheral white blood cell, lymphocyte, neutrophil, and monocyte counts after infusion of ⁹⁰Y-AC8 antibody in macaques.

**Fig. 2** Clearance of ⁹⁰Y-AC8 and ¹³¹I-AC8 antibody from blood. Percent of injected dose per gram of blood (mean ± SE) in a logarithmic scale.
measured by flow microfluometry. Low-dose BC8 cleared more slowly from blood and had a higher and more homogeneous uptake in lymph nodes than low-dose AC8. High-dose AC8 saturated all CD45 antigen sites on node lymphocytes. This difference in binding to antigenic sites was thought to be related to differences in avidity between the two antibodies, although an effect of different isotypes could not be excluded. The nontarget organs with the highest radiation uptake were lungs and liver. Low-dose 131I-AC8 antibody delivered estimated radiation absorbed doses 8 to 9 times higher to spleen, 2 to 3 times higher to marrow, and 2 times higher to lymph nodes than to lungs or liver.

In our study, 90Y-AC8 antibody delivered estimated radiation absorbed doses 5 to 7 times higher to spleen and 2 to 4 times higher to marrow than to lungs or liver. The estimated radiation absorbed dose to lymph nodes was 28% lower than the dose to liver and 10% higher than the dose to lungs. The high avidity of AC8 for macaque CD45 antigen may result in more rapid uptake by cells in tissues readily accessible to the circulation such as spleen and bone marrow than in lymph nodes (19). At the same antibody dose, the radiation delivered to lymph nodes with 131I was higher than that achieved with 90Y. We have observed similar results in limited, unpublished studies of 90Y-anti-CD45 antibody in mice. The reason for this finding is unclear, but it could be explained in part by differences in uptake and biological retention times in lymph nodes, or differences in physical half-life between both isotopes. Preliminary studies labeling anti-CD45 antibody with bismuth-213, an α emitter of shorter half-life, very high energy, and much shorter path length than 131I or 90Y have yielded similar results (28, 29).

Iodine-131 isotope was initially selected as the radiolabel for our clinical studies given its low cost, ready availability, long track record in the clinical setting, simple chemistry for radiolabeling, and capacity for imaging by using conventional planar nuclear scanning. Although these preclinical studies with directly labeled 90Y-AC8 antibody do not show a therapeutic advantage for 90Y compared with 131I, there are several reasons

---

**Fig. 3** Clearance of 90Y-AC8 and 131I-AC8 antibody from target and nontarget organs. Percent of injected dose per gram of tissue (mean ± SE) in a logarithmic scale.
to consider this radiometal immunoconjugate for future clinical use. First, its shorter physical half-life of 2.7 days matches the biological half-life of anti-CD45 antibody more closely than the 8-day physical half-life of $^{131}$I (5). In addition, the higher $\beta$-particle energy and resulting longer path length of $^{90}$Y could improve the homogeneity of radiation delivered to target tissues, particularly in the complex marrow environment in which trabecular bone may prevent penetration of the lower $\beta$-particle energy of $^{131}$I (20, 30, 31). There are also practical advantages to the use of $^{90}$Y in the clinical setting. A large number of patients treated in our clinical trials with anti-CD45 antibody labeled with high doses of $^{131}$I have developed hypothyroidism secondary to radioablation despite use of prophylactic thyroid blockade with iodine p.o. solution (5). This toxicity can be avoided by using $^{90}$Y, as shown by the low uptake of this gland on the macaque dosimetry model. Contrary to $^{131}$I, $^{90}$Y does not produce $\gamma$ emissions and does not require confinement of patients in radiation isolation rooms, a significant advantage in terms of health personnel safety and ease of treatment in the outpatient setting (32).

However, the lack of $\gamma$ emissions of $^{90}$Y also limits the utility of conventional planar nuclear imaging for direct determination of the concentration of this radionuclide in organs of interest. Because the standard method for evaluating the biodistribution of a radionabeled antibody is to measure the concentration of radioactivity uptake within each organ, several alternative imaging techniques for $^{90}$Y are being explored. The first and most studied technique involves $\gamma$ imaging using indium-111 as a surrogate isotope (33–35). The second involves measuring $^{90}$Y bremsstrahlung radiation (36–38). Positron emission tomography with the less readily available radionuclide yttrium-86 has also been studied and may potentially yield more accurate dosimetry results than $^{111}$In or bremsstrahlung imaging (39, 40). These techniques have been evaluated in studies of lymphoma, breast, hepatic, and gastrointestinal malignancies (38–43). There are no preclinical or clinical studies to date comparing the accuracy of these imaging methods.

Regardless of the radionuclide used, residual unbound radiolabeled antibody in the circulation and the resultant high levels of background radioactivity are obstacles to the optimal implementation of radioimmunotherapy, limiting the target to nontarget organ ratios of absorbed radiation that can be achieved. New radioimmunotherapy techniques are focusing on reducing the amount of unbound radiolabeled antibody from the circulation in an attempt to reduce toxicity to nontarget organs. One attractive approach, pretargeting, consists of a multistep process to dissociate the distribution phase of the antibody protein from the administration of the therapeutic radionuclide (44-48). A second approach is the removal of antibody from the circulation using extracorporeal adsorption therapy (49). We have initiated studies testing these approaches with anti-CD45 in a nonhuman primate model, with the goal to improve the ratios of radiation to target versus nontarget organs observed in the study described here.

Our study confirms that radiolabeled antibody reactive against CD45 antigen can deliver significantly greater radiation to target organs compared with nontarget organs. Labeling this antibody with $^{90}$Y resulted in therapeutic ratios similar to those observed previously with $^{131}$I. However, this comparison was limited by several factors. First, there were differences in the methods to obtain radiation absorbed dose estimates in the macaques treated with $^{131}$I or $^{90}$Y. For the initial studies with $^{131}$I the data were obtained from both $\gamma$ imaging (indirect) and direct quantification of tissue radioactivity, which allowed for determination of dosimetry for each individual animal. For the $^{90}$Y studies, only direct quantification methods were used, thus not allowing determination of dosimetry for each animal but rather for an average animal. We attempted to compensate for this lack of imaging data by studying the largest number of animals per time point possible. However, our ability to study an even larger number of animals was limited by the financial and ethical constraints of research with primates. Despite these limitations, this study provides important information about the feasibility of $^{90}$Y-labeled anti-CD45 antibody therapy and extensive quantitative data of the biodistribution of this radioimmunoconjugate in a nonhuman primate model, both of utility for the design of future clinical trials.

### Table 1: Organ dosimetry of $^{90}$Y-AC8 antibody for a theoretical average animal

<table>
<thead>
<tr>
<th>Organ</th>
<th>cGy/mCi*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target organs</strong></td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>2,120</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>1,060</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>315</td>
</tr>
<tr>
<td><strong>Nontarget organs</strong></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>440</td>
</tr>
<tr>
<td>Lungs</td>
<td>285</td>
</tr>
<tr>
<td>Kidneys</td>
<td>136</td>
</tr>
<tr>
<td>Adrenal glands</td>
<td>108</td>
</tr>
<tr>
<td>Cortical bone</td>
<td>89.2</td>
</tr>
<tr>
<td>Heart wall</td>
<td>39.5</td>
</tr>
<tr>
<td>Testes</td>
<td>35.3</td>
</tr>
<tr>
<td>Thymus</td>
<td>30.1</td>
</tr>
<tr>
<td>Muscle</td>
<td>30</td>
</tr>
<tr>
<td>Pancreas</td>
<td>25.2</td>
</tr>
<tr>
<td>Thyroid gland</td>
<td>25.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>24.8</td>
</tr>
<tr>
<td>Gallbladder wall</td>
<td>17.1</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>12.8</td>
</tr>
<tr>
<td>Small intestines</td>
<td>12.4</td>
</tr>
<tr>
<td>Whole body</td>
<td>11.9</td>
</tr>
<tr>
<td>Colon</td>
<td>11.3</td>
</tr>
<tr>
<td>Brain</td>
<td>3.3</td>
</tr>
<tr>
<td>Skin</td>
<td>1.3</td>
</tr>
</tbody>
</table>

*Estimated radiation absorbed doses per millicurie of $^{90}$Y injected.

### Table 2: Comparison of therapeutic ratios for $^{90}$Y- and $^{131}$I-AC8 antibody

<table>
<thead>
<tr>
<th>Ratio*</th>
<th>$^{90}$Y-AC8</th>
<th>$^{131}$I-AC8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen:liver</td>
<td>4.8</td>
<td>9.1</td>
</tr>
<tr>
<td>Marrow:liver</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Lymph nodes:liver</td>
<td>0.7</td>
<td>2.0</td>
</tr>
<tr>
<td>Spleen:lymphs</td>
<td>7.4</td>
<td>7.9</td>
</tr>
<tr>
<td>Marrow:lymphs</td>
<td>3.7</td>
<td>2.2</td>
</tr>
<tr>
<td>Lymph nodes:lymphs</td>
<td>1.1</td>
<td>1.7</td>
</tr>
</tbody>
</table>

*Results represent the average target-to-nontarget organ ratio of radiation after injection of 0.5 mg/kg of antibody labeled with $^{90}$Y ($n = 12$) or $^{131}$I ($n = 3$; ref. 19).
REFERENCES


35. Cremonesi M, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide:
Biodistribution of Yttrium-90–Labeled Anti-CD45 Antibody in a Nonhuman Primate Model


Updated version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/11/2/787

Cited articles This article cites 47 articles, 25 of which you can access for free at: http://clincancerres.aacrjournals.org/content/11/2/787.full#ref-list-1

Citing articles This article has been cited by 6 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/11/2/787.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.